BiTE antibodies could unlock transplants for 'Incompatible' kidney patients
NCT ID NCT07689149
First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time
Summary
This trial tests two BiTE drugs (blinatumomab and teclistamab) in 20 adults with end-stage kidney disease who have very high antibody levels (cPRA ≥90%) and have waited over 5 years for a transplant. The goal is to safely lower these antibodies enough to make a kidney transplant possible. Participants receive one of the two drugs in a short, low-dose regimen, and researchers track antibody reduction, side effects, and whether transplantation occurs within a year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Blinatumomab and Teclistamab (BiTE drugs)
- What this could lead to
- If successful, this approach could help highly sensitized patients receive a kidney transplant by safely reducing harmful antibodies.
- What could go wrong
- This is a small early-phase trial with only 20 participants. BiTE drugs can cause serious side effects like cytokine release syndrome and neurotoxicity. The treatment may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for END-STAGE RENAL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Which diuretic protects a new kidney best? a Head-to-Head trial puts furosemide and mannitol to the test
- Can a new drug combo help kidney transplants last longer?
- Ultrasound may fine-tune fluid balance in dialysis patients — a trial puts it to the test
- Dialysis patients may straighten up with In-Chair exercise
- New nerve block may cut opioid use after kidney transplants
- Could pumpkin seed oil ease inflammation in dialysis patients?